Maternal adverse effects of therapy · women at risk of preterm birth
Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
Dexamethasone showed no clear difference in respiratory distress syndrome compared with betamethasone – fetal/neonatal outcomes (high certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
Dexamethasone showed no clear difference in intraventricular haemorrhage compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
Dexamethasone showed no clear difference in chronic lung disease compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
Dexamethasone showed no clear difference in necrotising enterocolitis compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema
Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Twice daily or more showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with once daily topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Twice daily or more showed no clear difference in patient‐reported symptoms of eczema: PGA (number with cleared or… compared with once daily topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
Moderate‐potency may leads to lower patient‐reported symptoms of eczema: 1‐5 weeks compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema · people with eczema
1 finding from 1 review